Pilot Study of efficacy and safety of nalfurafine hydrochloride for jaundice associated pruritus

Pilot Study of efficacy and safety of nalfurafine hydrochloride for jaundice associated pruritus - Pilot Study of efficacy and safety of nalfurafine hydrochloride for jaundice associated pruritus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033255

Enrollment

Registered

2018-07-04

Start date

2018-07-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus

Interventions

nalfuraine hydrochloride group fexofenadine hydrochloride group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obstructive jaundice patients with hyperbilirubinemia (serum bilirubin levels are over 3mg/dL). Chronic hepatitis patients diagnosed with blood test and/or imaging examination. Patients have itchiness. Informed consent must be obtained from patients themselves.

Exclusion criteria

Exclusion criteria: Patient's consciousness are not alert. Presence of hypersensitivity to nalfurafine hydrochloride and/or fexofenadine hydrochloride. Presence of other dermatosis except for jaundice associated pruritis. Presence of sever organopathy and/or drug allergy. Patients who pregnant or possibility of pregnant, lactating and desire for childbearing. Difficult to ingestion. Ineligible cases are judged by researchers.

Design outcomes

Primary

Measure	Time frame
Compare with curative effect for pruritus in 2 weeks later medicating between "nalfurafine hydrochloride group" and "fexofenadine hydrochloride group".	—

Countries

Japan

Contacts

Public ContactRyo Shimizu

Wakayama Medical University Second Department of Internal Medicine

rshimizu@wakayama-med.ac.jp+81734472300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026